AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02600130 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: via peripheral intravenous infusion
Study NCT02548962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study NCT02548962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study NCT02548962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02548962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03058770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor retraining
Description: Subjects will receive education regarding sensation and sensory retraining; practice in detection and localization of touch and in discrimination of hardness, texture and temperature in sitting and standing with vision obscured; proprioception training; and practice of these sensations in functional activities.
Study NCT03058770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation technique
Description: Subjects will perform guided relaxation by using the Jacobson technique.
Study NCT02473952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGIV-C
Description: IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified
Study NCT02473952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00440765 — intervention group
Intervention type: DRUG
Intervention: bortezomib
Description: dose as determined (observational study) by treating physician
Study NCT00823719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab + ICE
Description: 3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 milligrams (mg); cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg~ICE regimen:~ifosfamide + mesna - 5 grams (g)/meters squared (m\^2)/24 hours (hrs) continuous on day 2 of dosing cycle; carboplatin - AUC 5 (800 mg maximum) on day 2 of dosing cycle; etoposide - 100 mg/m\^2 on days 1, 2 and 3 of dosing cycle.
Study NCT00823719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab + DHAP
Description: 3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg.~DHAP regimen:~dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m\^2/24 hrs continuous on day 1 of dosing cycle; cytarabine - 2 g/m\^2 q12 hrs (2 doses) on day 2 of dosing cycle.
Study NCT00965913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: 15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
Study NCT00965913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch Comparator
Description: 15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
Study NCT00965913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
Study NCT02726737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate
Study NCT02726737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT02726737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT02726737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sterile distilled water
Study NCT02366065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
Study NCT03633019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: high dose rhTPO ih
Study NCT03264079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl capsules 10 mg
Description: One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial
Study NCT03264079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole capsules 100 mg
Description: Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial
Study NCT02883387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative CT angiography
Description: Patients will receive a CT scan to map the blood vessels to be used during surgery for breast reconstruction
Study NCT02883387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Preoperative Imaging
Description: No imaging will be done to map blood vessels prior to surgery
Study NCT02414854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Study NCT03669029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg
Description: Clinical response at week 6,14, 30 and 54 will be correlated to serum golimumab levels and anti-golimumab antibody levels.
Study NCT03669029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab treatment optimization.
Description: Golimumab dosing will be optimized in patients without clinical response at week 6.
Study NCT02563912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handbook
Description: Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
Study NCT02563912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication chart
Description: Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
Study NCT04154124 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR scan
Description: whole-body PET/CT scan and pelvic PET/MR scan (MR protocol will include three plane fast spin echo T2 weighted, DWI and dynamic contrast enhanced imaging). The ad interim assessment will use a pelvic PET/MR scan only (without PET/CT), to avoid the radiation associated with whole body CT. In the staging and post-nT assessment, the addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
Study NCT00649012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone HCl Tablets 45 mg
Description: 45mg, single dose fed
Study NCT00649012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actos® Tablets 45 mg
Description: 45mg, single dose fed
Study NCT01847846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP mask - prototype
Description: prototype mask, wore for all sleeps for 4 and 8 weeks (as randomly selected). Mask to be used in conjunction with participant's usual prescribed CPAP settings.
Study NCT00546728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: exenatide 10 mcg twice daily
Study NCT00546728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 500 twice daily
Study NCT04066218 — intervention group
Intervention type: OTHER
Intervention: Interviews
Description: * Participation will serve as verbal consent.~* Qualitative PRA will call participant to schedule either phone or in person interview. If via phone, the study PRA performing the interview, will remind them to find a private space to speak.~* REDCap link will be sent for PROMIS SexFS Brief.~* PRA will perform semistructured interview and guide Think-Aloud to complete the PROMIS SexFS Brief.~* Participants will not submit responses to PROMIS SexFS Brief responses after completing the tool.
Study NCT03750487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-screening & brief intervention (e-SBI)
Description: Computer-delivered screening and brief motivational intervention targeting alcohol and drug use + goal-setting and content reinforcement
Study NCT03750487 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control e-SBI
Description: Computer-delivered screening and brief motivational intervention targeting healthy eating and exercise
Study NCT02414854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Study NCT02414854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) therapy
Description: Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)
Study NCT02414854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled corticosteroid (ICS) therapy
Description: Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)
Study NCT02414854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Oral inhalation as needed
Study NCT02414854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol
Description: Oral inhalation as needed
Study NCT02414854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol/Levosalbutamol
Description: Oral inhalation as needed
Study NCT02414854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levalbuterol/Levosalbutamol
Description: Oral inhalation as needed
Study NCT00830388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% Foam
Description: Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.
Study NCT02260141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: d-ribose
Description: giving ribose in those with a diagnosis of Alzheimer's and/or dementia
Study NCT01430104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Administered subcutaneously during the Treatment Period
Study NCT01430104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspara-CA 600 mg
Description: Administered orally throughout the study
Study NCT01430104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfarol 1.0 µg
Description: Administered orally throughout the study
Study NCT01861119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silicone gel Kelo-cort™;
Study NCT01861119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onion extract gel Contractubex™
Study NCT00472706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: excision
Description: excision 3 mm margin
Study NCT00472706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: Photodynamic therapy
Study NCT01440595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir 100 mg tablets once daily for 12 weeks.
Study NCT01440595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Grazoprevir
Description: Placebo to Grazoprevir once daily for 12 weeks
Study NCT01440595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (Peg-IFN)
Description: Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
Study NCT01440595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2b (Peg-IFN)
Description: Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
Study NCT02508311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Albuterol Extended Release
Description: Subjects will receive extended release Albuterol, 4mg twice daily for the first week. The remaining 15 weeks subjects will receive extended release Albuterol, 8mg twice daily.
Study NCT02508311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo tablets twice daily for 16 weeks.
Study NCT02635815 — intervention group
Intervention type: PROCEDURE
Intervention: Upper gastrointestinal endoscopy
Description: Upper gastrointestinal endoscopy using the Pentax video endoscope EG 3440
Study NCT02169674 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EngerixB, GlaxoSmithKline Vaccines
Study NCT01440595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
Study NCT01440595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
Study NCT01572428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inspection with Narrow-Band Imaging(NBI)
Description: Narrow-Band Imaging(NBI)of the colon rather than the standard white light in the inspection of the colon during colonoscopy.
Study NCT01572428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard White Light
Description: Use of Standard White Light on the colon rather than Narrow-Band Imaging(NBI)in the inspection of the colon during a colonoscopy.
Study NCT03334916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YMC026
Description: YMC026 20mL TID
Study NCT03334916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20mL TID
Study NCT02606838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Styx Lancing Device
Description: Untrained Persons With Diabetes used the Styx Lancing Device with 28 and 30 Gauge lancets to obtain fingerstick and Alternate Site palm capillary blood. Study Staff tested the capillary blood using Contour NEXT Blood Glucose Meters (BGMs) and recorded the results. Meter results could be numeric, non-numeric (ie, error messages), or not obtained at all.
Study NCT03769623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biolimus
Description: 103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Biolimus
Study NCT03769623 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powerline
Description: 103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Powerline
Study NCT02696317 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses with HydraLuxe™
Description: Contact lenses worn during Period 1 or 2, as randomized
Study NCT02696317 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Description: Contact lenses worn during Period 1 or 2, as randomized
Study NCT03004638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI6012 300 mg
Description: Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
Study NCT03004638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV Push
Description: Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
Study NCT03004638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI6012 IV Push
Description: Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
Study NCT02060838 — intervention group
Intervention type: PROCEDURE
Intervention: Acute normovolemic hemodilution (ANH)
Description: Blood is drawn from our patients pre-bypass after obtaining the arterial line and administered back to the patient after separation from cardiopulmonary bypass (CPB) and reversal of heparin with protamine.
Study NCT03486808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IFG stimulation
Description: stimulating left inferior frontal cortex with transcranial direct current stimulation for 30 minutes
Study NCT03486808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IFG stimulation
Description: stimulating left inferior frontal cortex with transcranial direct current stimulation for 30 minutes
Study NCT04126733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Regorafenib administered as oral tablets given every day for 3 weeks of each 28 days treatment cycle (i.e., 3 weeks on, 1 week off)
Study NCT01193803 — intervention group
Intervention type: PROCEDURE
Intervention: Microbiological cultures and Molecular biology
Description: Biological/Vaccine: Microbiological cultures and Molecular Biology Bacteriological procedures: All solid specimens will be crushed using a mechanic apparatus. Direct examination and cultures will be performed according to the guidelines applied for osteoarticular infections. Cultures and subcultures will be incubated for 15 days to 3 months for Mycobacteria.~Molecular procedures: DNA extraction will be based on Boom's method (QIAGEN kit and EZ1 BioRobot). Detections of bacteria will be performed by amplification and sequencing of the 16S rRNA gene. Some specific detections as the detection of Staphylococcus sp. and Mycobacterium tuberculosis will be added to this protocol.
Study NCT03398538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
Study NCT03398538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
Study NCT03398538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional (outer) Dressing Application
Description: Application of outer a moisture retentive dressing, and a multi-layer compression dressing.
Study NCT03398538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional (outer) Dressing Application
Description: Application of outer a moisture retentive dressing, and a multi-layer compression dressing.
Study NCT04126733 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab (Opdivo)
Description: Administered on day 1 of every treatment cycle.
Study NCT03835975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: Pneumococcal conjugate vaccine
Study NCT03835975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal polysaccharide vaccine
Study NCT03398538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirragen Wound Matrix Dressing
Description: Application of Mirragen to wound site along with standard of care treatment
Study NCT03398538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibracol Wound Dressing
Description: Application of Fibracol Alginate along with standard of care treatment
Study NCT00620308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-NP
Description: One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
Study NCT00620308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose 5% in water (the vehicle)
Study NCT05321524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 0.1mg
Description: Tablets administered orally once daily.
Study NCT05321524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 1.5mg
Description: Tablets administered orally once daily.
Study NCT05321524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 5mg
Description: Tablets administered orally once daily.
Study NCT03317704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speed endurance training
Description: Speed endurance training
Study NCT02855099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The duration on the rehabilitation will be 3 month and will be a multidisciplinary program that includes supervised physical activity
Study NCT05219240 — intervention group
Intervention type: OTHER
Intervention: 20Lighter Program
Description: Visceral Adiposity-Focused Anti-Obesity Telehealth Program
Study NCT03835975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: Pneumococcal conjugate vaccine
Study NCT02706158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1500 mg Calcium and 1200 IU Vitamin D for 2 months
Description: 1500 mg Calcium and 1200 IU Vitamin D for 2 months
Study NCT02706158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: balanced diet
Description: participants will get a balanced diet according to pregnancy stage
Study NCT02159482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2a
Study NCT00648076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium Extended-Release Tablets 500 mg
Description: 500mg, single dose fed